8169
From September 1st, 2017, healthcare facilities and institutions funded from state and local budgets will start public procurement of medicines included in the new National List of Essential Medicines
7075
Budget procurement of medicines by healthcare institutions in Ukraine is carried out at the prices announced by the government, therefore it will be difficult to prosecute heads of clinics for inflating prices
10126
Dmytro Aleshko, partner at Legal Alliance Company Ukrainska Pravda This autumn great and tangible changes to healthcare sector in Ukraine will be made. Start
6694
Natalia Spivak, associate of Legal Alliance Company The medical products industry, including medical equipment, is one of the most progressive industries in th
10780
Andrii Gorbatenko, associated partner at Legal Alliance Company
On June 30th, 2017, draft Order of the Antimonopoly Committee of Ukraine (the AMCU) "On Approvi
7567
Regulation of pharmaceutical activities is a relatively young area of law, whose development over the last decade has gained significant momentum.
6553
Alexander Bondar, senior associate at Legal Alliance CompanyZoia Zamikhovska, associate at Legal Alliance CompanyFor more than a year the medical (pharmaceutica
8883
Review of the Annual Report of the Antimonopoly Committee of Ukraine on the Pharmaceutical Industry
The Antimonopoly Committee of Ukraine issued a report for 2016. The first thing that catches our eye is form of the report. This is the first report of the Antimonopoly Committee of Ukraine, and indeed the first report of a state body (at least from those that I have seen) presented in a graphic illustrative form.
5690
In the beginning of the 2017 our company ran a survey among the clients, mostly international pharmaceutical companies and their representative offices in Ukraine, to define the main challenges of the pharmaceutical market in Ukraine of 2016.
9548
The entry into force of amendments to the TRIPS allows the developed states to issue compulsory licenses to generic pharmaceutical companies for the production of medicinal products, allowing them to export the product to developing countries. This mechanism is very interesting for the domestic pharmaceutical industry.
